Innoveren Scientific Revenue

In the year 2022, Innoveren Scientific had annual revenue of $453.46K, down -71.86%.

Revenue (ttm)

$453.46K

Revenue Growth

-71.86%

P/S Ratio

0.01

Revenue / Employee

$807,455

Employees

Market Cap

18.22K

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2022	453.46K	-1.16M	-71.86%
Dec 31, 2021	1.61M	-539.15K	-25.07%
Dec 31, 2020	2.15M	-6.20M	-74.23%
Dec 31, 2019	8.35M	463.74K	5.88%
Dec 31, 2018	7.88M	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
UnitedHealth Group	379.49B
Johnson & Johnson	78.71B
Merck & Co.	61.40B
AbbVie	54.40B
AstraZeneca	49.13B
Novartis AG	48.86B
Thermo Fisher	42.49B
Abbott Laboratories	40.33B

Revenue Rankings

IVRN News

5 months ago - Innoveren Scientific Announces 510(k) Submission for SkinDisc(TM) Lite - Accesswire
10 months ago - Innoveren Scientific Divests Device & Receives Capital Infusion - Accesswire
1 year ago - H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scion Solutions, LLC - GlobeNewsWire
2 years ago - H-CYTE Announces Intent to Acquire SkinDisc, Expects to Complete Within 30 Days - GlobeNewsWire
2 years ago - H-CYTE Completes Acquisition of Jantibody - GlobeNewsWire
2 years ago - H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days - GlobeNewsWire
2 years ago - H-CYTE Announces 1-for-1,000 Reverse Stock Split - GlobeNewsWire
2 years ago - H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise - GlobeNewsWire

More News